- Investor's Business Daily•5 hours ago
Biotech stocks have made big gains in 2017, but not all companies are winners.
- PR Newswire•8 days ago
SAN FRANCISCO, April 20, 2017 /PRNewswire/ -- Nektar Therapeutics (NKTR) today announced that it will host an analyst and investor event with clinical investigators on Saturday, June 3, 2017 at 6:00 pm CDT in Chicago, IL during the 2017 American Society of Clinical Oncology (ASCO) Meeting. Presenters will include Dr. Adi Diab, Assistant Professor, Melanoma Medical Oncology at the University of Texas MD Anderson Cancer Center, Dr. Nizar Tannir, Professor, Genitourinary Medical Oncology at the University of Texas MD Anderson Cancer Center and Dr. Michael Hurwitz, Assistant Professor of Medicine (Medical Oncology) at Yale Cancer Center.
- Motley Fool•9 days ago
NKTR-181's ability to tackle back pain potentially positions it for an FDA application for approval.
NKTR : Summary for Nektar Therapeutics - Yahoo Finance
Nektar Therapeutics (NKTR)
NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
|Bid||18.93 x 400|
|Ask||18.96 x 200|
|Day's Range||18.74 - 19.28|
|52 Week Range||11.41 - 24.88|
Trade prices are not sourced from all markets
|PE Ratio (TTM)||-17.19|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|